{"id":"W4392820515","doi":"10.1136/jitc-2023-008409","title":"Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Oxaliplatin; Nivolumab; Oncology; Colorectal cancer; Clinical endpoint; Irinotecan; Randomized controlled trial; Progression-free survival; Phases of clinical research; Clinical trial; Cancer; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008691929,0.000313034,0.001863192,0.00007632459,0.0002261055,0.00005035992,0.00009381356,0.000071175,0.00004437387],"category_scores_gemma":[0.0001414459,0.0001498894,0.0007684783,0.0001222909,0.0003588697,0.00007792454,0.00001069669,0.000137627,1.156975e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003954742,"about_ca_system_score_gemma":0.0008074981,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00172984,"about_ca_topic_score_gemma":0.001548316,"domain_scores_codex":[0.9977259,0.000117644,0.00126807,0.0003249969,0.0003045397,0.000258848],"domain_scores_gemma":[0.9967537,0.002011264,0.0006637939,0.0001850621,0.0003053005,0.00008091318],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8182841,0.0005794413,0.00008846042,0.00008435381,0.01168511,0.000005531146,0.002791371,0.0001099669,0.0002596647,0.00002238184,0.0003385009,0.1657511],"study_design_scores_gemma":[0.9473658,0.02424269,0.0002379035,0.0006999504,0.004533099,0.00002386363,0.0002262252,0.006805096,0.002200099,0.0003961865,0.01309769,0.0001714606],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8936414,0.09442472,0.001059345,0.003143986,0.001204313,0.00481585,0.001660127,0.00001866888,0.00003160226],"genre_scores_gemma":[0.9169016,0.07855006,0.0009374176,0.00007504555,0.0007611283,0.001940644,0.00004240936,0.00005588571,0.0007358173],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1655797,"threshold_uncertainty_score":0.6112312,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08274832123584072,"score_gpt":0.438821214677889,"score_spread":0.3560728934420483,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}